| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/06/2005 | WO2005000784A2 5-[phenyl, tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl- cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity |
| 01/06/2005 | WO2005000353A1 Serum cholesterol lowering agnet or preventive or therapeutic agent for atherosclerosis |
| 01/06/2005 | WO2005000343A1 Use of a clostridial toxin to reduce appetite |
| 01/06/2005 | WO2005000339A2 Melanocortin receptor 4(mc4) agonists and their uses |
| 01/06/2005 | WO2005000338A1 Uses of melanocortin-3 receptor (mc3r) agonist peptides |
| 01/06/2005 | WO2005000325A2 Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus |
| 01/06/2005 | WO2005000318A2 Method of inducing apoptosis and inhibiting cardiolipin synthesis |
| 01/06/2005 | WO2005000301A1 2-aminobenzothiazoles as cb1 receptor inverse agonists |
| 01/06/2005 | WO2005000300A1 Substituted 5-membered ring compounds and their use |
| 01/06/2005 | WO2005000299A1 Compositions comprising balaglitazone and further antidiabetic compounds |
| 01/06/2005 | WO2005000286A1 Composition for relieving or lessening fatigue and medical device fitted with the composition |
| 01/06/2005 | WO2004101528A3 Isoquinoline derivatives and their use as gfat inhibitors |
| 01/06/2005 | WO2004082574A3 Diagnostics and therapeutics for diseases associated with dopamine receptor d5 (drd5) |
| 01/06/2005 | WO2004073588A3 Diagnostics and therapeutics for diseases associated with g protein coupled receptor r35 (r35) |
| 01/06/2005 | US20050005329 Isolated nucleotide sequence encoding polypeptide derived from algae Isochrysis galbana; expression of vector results in production of polyunsaturated fatty acid; use in pharmaceutical compositions, animal feeds and cosmetics |
| 01/06/2005 | US20050005328 Nucleotide sequence encoding a polypeptide derived from fungus Thraustochytrium aureum; expression of vector results in production of polyunsaturated fatty acid (omega 6-docosapentaenoic acid and docosahexaenoic acid); use in pharmaceutical compositions, animal feeds and cosmetics |
| 01/06/2005 | US20050004363 4-oxoimidazolidine-2-spiropiperidine derivatives |
| 01/06/2005 | US20050004360 Compounds and methods for modulation of estrogen receptors |
| 01/06/2005 | US20050004348 Sodium transport protein for use as tool in identifying modulator for treatment of hyperphosphatemia or hypophosphatemia |
| 01/06/2005 | US20050004222 Methods for prevention and treatment of gastrointestinal disorders |
| 01/06/2005 | US20050004213 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity |
| 01/06/2005 | US20050004208 Different solubilities and/or dissolution rates and flow properties. |
| 01/06/2005 | US20050004206 suspending crystal strutured or amorphous lipitor in diluents comprising alcohols and/or water mixtures to cause conversion, then separating the diluents; monodispersity |
| 01/06/2005 | US20050004205 Such as 1-[N alpha -(1'-Acetoxyethoxycarbonyl)-N omega -(pyrazinyl-2-carbonyl)-L-ornithinyl]-pyrrolidine-2-carbonitrile; impaired glucose tolerance, type II diabetes, hypoglycaemia |
| 01/06/2005 | US20050004202 Such as 3-[1-(3-methoxypropyl )-1H-indazol-3-yl]-4-[1-(3-pyridinyl )-1H-indol-3-yl]-1H-pyrrole-2,5-dione; protein kinase C and/or glycogen synthase kinase-3 diseases |
| 01/06/2005 | US20050004195 Inhibitors of phosphoinositide 3 kinases; inflammatory diseases, cardiovascular disorders, cancers; such as 5,6-dimethoxy-3-o-tolylsulfanyl-1H-indole-2-carboxylic acid-(2H-tetrazol-5-yl)-amide |
| 01/06/2005 | US20050004190 (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]-acetanilide; free base forms; stability; moisture resistance |
| 01/06/2005 | US20050004187 Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents |
| 01/06/2005 | US20050004183 for preventing, Syndrome X, diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases; peroxisome proliferator activated receptor (PPAR) |
| 01/06/2005 | US20050004167 Such as dibenzofuran-2-carboxylic acid 2-(phenylsulfonyl)hydrazide |
| 01/06/2005 | US20050004165 Composition and method for modulating BAR/FXR receptor activity |
| 01/06/2005 | US20050004153 inhibitors of Lymphocyte Function-associated Antigen 1 (LFA-1)/intercellular adhesion molecule (ICAM); use treating transplant rejection, rheumatoid arthritis, diabetes, inflammatory bowel disease, and chronic obstructive pulmonary disease; 2,4-dioxo-1,3,7-triazaspiro[4.4]nonanes |
| 01/06/2005 | US20050004152 Thiazole compounds useful as inhibitors of protein kinase |
| 01/06/2005 | US20050004149 Pyrimidine compound and medicinal composition thereof |
| 01/06/2005 | US20050004142 furo(2,3-d)pyrimidine and thieno(2,3-d)pyrimidine compounds for treating cancer and hyperproliferative diseases; receptor tyrosine kinase inhibitors |
| 01/06/2005 | US20050004140 Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states |
| 01/06/2005 | US20050004135 Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| 01/06/2005 | US20050004134 Adenosine antagonists; having 6-oxo-1,6-dihydro-3-pynidazinyl functionality; synthesis |
| 01/06/2005 | US20050004132 Pain, immune diseases, inflammatory disorders; low toxicity; such as 1-[2-(3-(4-Pyridyl)phenyl)ethyl]-4-(3-(trifluoromethyl)phenyl)-1,2,3,6-tetrahydropyridine 1-oxide |
| 01/06/2005 | US20050004125 Such as 4-[[4-(1-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]-benzonitrile; bipolar disorder, pain, type 2 diabetes |
| 01/06/2005 | US20050004124 Synergistic mixture; antidiabetic agents; antiischemic agents |
| 01/06/2005 | US20050004119 Trypsin like serine protease enzyme inhibitors |
| 01/06/2005 | US20050004116 Triazole inhibitors of type 2 methionine aminopeptidase |
| 01/06/2005 | US20050004115 such as 4-(4-(2-Fluorobenzyloxy)phenyl)-4-oxobutyric acid; for treatment of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis |
| 01/06/2005 | US20050004114 Heterocycle substituted carboxylic acids |
| 01/06/2005 | US20050004110 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease |
| 01/06/2005 | US20050004109 Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia |
| 01/06/2005 | US20050004101 Therapy for schizophrenia, obsessive complusive disorders; antidepressants; anxiolytic agents; panic disorders; antiepileptic agents; analgesics; headaches; sleep disorders; eating disorders |
| 01/06/2005 | US20050004082 Ether compounds |
| 01/06/2005 | US20050004077 Antidiabetic agents ; bioavailability |
| 01/06/2005 | US20050004056 Ptp10d, tec protein tyrosine kinase and edtp homologous proteins involved in the regulation of energy homeostasis |
| 01/06/2005 | US20050003997 Reduce body mass; obesity therapy; hyperlipemia; insulin resistance; atherosclerosis; antidiabetic agents; hypotensive agents |
| 01/06/2005 | US20050003976 Mixture of vegetable oils, aromatic solvent and caffeine; nerve stimulant perfume; topical applying |
| 01/06/2005 | US20050003493 Kit comprising immunoblobulins which bind the bioactive, three-dimensional epitope of parathyroid hormone for use in classifying hypercalcemic disorders |
| 01/06/2005 | US20050003492 Novel polypeptide |
| 01/06/2005 | US20050003457 Immunoglobulin which binds osteoclastogenesis inhibitory factor binding molecules (OBM)) and prevents bone resorption for use in treatment and prevention of bone disorders |
| 01/06/2005 | US20050003442 Delta4-desaturase genes and uses thereof |
| 01/06/2005 | US20050003400 Using osteoprotegrin binding agent as tool in identifying modulator for treatment and prevention of osteoporosis and bone disorders |
| 01/06/2005 | US20050003353 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor |
| 01/06/2005 | US20050003352 Comprises recombinant mitochondrial transport protein for diagnosis, prevention and treatment of alzheimer's, diabetes, parkinson's, huntington's, cancers |
| 01/06/2005 | US20050002988 Nutritional composition for controlling blood sugar level |
| 01/06/2005 | CA2531058A1 Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus |
| 01/06/2005 | CA2531020A1 Cannabinoid receptor modulator |
| 01/06/2005 | CA2530662A1 Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof |
| 01/06/2005 | CA2530228A1 Compositions comprising balaglitazone and further antidiabetic compounds |
| 01/06/2005 | CA2530024A1 Melanocortin receptor 4(mc4) agonists and their uses |
| 01/06/2005 | CA2529010A1 Use of a clostridial toxin to reduce appetite |
| 01/06/2005 | CA2528785A1 2-amidobenzothiazoles as cb1 receptor inverse agonists |
| 01/06/2005 | CA2528591A1 Glp-1 analog fusion proteins |
| 01/06/2005 | CA2527881A1 Uses of melanocortin-3 receptor (mc3r) agonist peptides |
| 01/05/2005 | EP1493743A1 Substituted bipiperidine intermediates and derivatives thereof |
| 01/05/2005 | EP1493742A1 Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders |
| 01/05/2005 | EP1493443A1 Use of pyridoxal phosphate for the treatment of diabetes and related complications |
| 01/05/2005 | EP1493437A1 Compositions for diabetes |
| 01/05/2005 | EP1492868A2 Method of modulating inflammatory response |
| 01/05/2005 | EP1492796A1 Substituted amino isoxazoline derivatives and their use as anti-depressants. |
| 01/05/2005 | EP1492793A1 New-4-(pyrrolopyrimidin-6-yl)benzenesulphonamide derivatives |
| 01/05/2005 | EP1492792A2 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino 4,5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments |
| 01/05/2005 | EP1492789A1 Tropane derivatives as ccr5 modulators |
| 01/05/2005 | EP1492788A1 Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity |
| 01/05/2005 | EP1492787A2 (condensed) pyrimidone and (condensed) pyridone compounds, processes for their preparation, and pharmaceutical compositions containing them |
| 01/05/2005 | EP1492785A1 New compounds |
| 01/05/2005 | EP1492784A2 Substituted 2,3-diphenyl pyridines |
| 01/05/2005 | EP1492780A1 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as ptpase 1b inhibitors |
| 01/05/2005 | EP1492779A1 Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity |
| 01/05/2005 | EP1492777A1 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidase inhibitors |
| 01/05/2005 | EP1492774A2 Pyrimidone derivatives useful for the treatment of inflammation and immunological diseases |
| 01/05/2005 | EP1492761A2 Amino acids with affinity for the alpha-2-delta-protein |
| 01/05/2005 | EP1492757A1 (2-((2-alkoxy)-phenyl)-cyclopent-1-enyl) aromatic carbo- and heterocyclic carboxylic acid and derivatives |
| 01/05/2005 | EP1492756A1 Novel thyroid receptor ligands |
| 01/05/2005 | EP1492571A2 Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands |
| 01/05/2005 | EP1492569A1 Aqueous dispersible steryl ester compositions |
| 01/05/2005 | EP1492555A2 Compositions and methods for modulation of effects on phagocyte and lymphoid cell population |
| 01/05/2005 | EP1492553A2 Cg8327, cg10823, cg18418, cg15862, cg3768, cg11447 and cg16750 homologous proteins involved in the regulation of energy homeostasis |
| 01/05/2005 | EP1492549A1 Compositions and methods for augmenting kidney function |
| 01/05/2005 | EP1492546A1 Use of pyrimidine nucleotides for the treatment of affections of the peripheral nervous system |
| 01/05/2005 | EP1492542A1 Hormone replacement therapy |
| 01/05/2005 | EP1492541A1 Pharmaceutical compositions comprising a 11-beta hydroxysteroid dehydrogenase inhibitor and a diuretic agent |
| 01/05/2005 | EP1492533A1 N-substituted pyridinone and pyrimidinone derivatives for use as lp-pla2 inhibitors in the treatment of artherosclerosis |
| 01/05/2005 | EP1492528A1 Antidiabetic agents |